

Revolutionary Biodegradable Mg based Implants

by Shanghai Innovation Medical Tech Co. Ltd.



沪创医疗科技有限公司
Shanghai Innovation Medical Technology Co. Ltd

Business Summary


Shanghai Innovation Medical Tech Co. Ltd. is a medical device company focusing on novel biodegradable Mg-based bone implants. Our clients are patients with orthopedic diseases who need to use bone implants for therapy. Unlike our competitors, who sell the traditional non-degradable bone implants, our clients could avoid the secondary surgery for removal and shorten the recovery time. By far we have already conducted 14 clinical trials in China, and all patients have good recovery. Hopefully our products will be approved for clinical application within 3 years.

Customer Problem

The conventional bone implants such as stainless steel, titanium alloy, etc. could probably bring inflammation and allergy during long term implantation, and therefore require secondary surgery to remove after bone healing, which increases the risk and economic cost for the patients.

Our Solution

Using biodegradable Mg-based bone implants could avoid second surgery, and save the medical cost up to 40% compared to traditional Ti implants. Moreover, it facilitates a faster recovery, and 20% recovery time will be saved.



Target market

- China is entering an aging society, and 3M patients per year require secondary surgery to remove bone implants after recovery.
- Global market will rise up to \$70 billion by 2023, with 15%/y growth.

Competitors

- Traditional Ti & Stainless Steel bone implants company.
- Syntellix AG, a Germany company producing Magnezix(WE43*) biodegradable Mg screws with CE license.

Competitive Advantage

Our Mg implants products have controllable biodegradation, lower cost (20% lower), and higher performance.

Customers & Partners

14 clinical trials have been performed and verified the advantages of our products, having drawn much interest from surgeons.

Revenue Model

The revenue will mainly come from bone screws/plates sales, and license authorizing to domestic partners.

Exit Strategy

Another medical devices company have already shown its interest and inquire the possibility of acquisition. Moreover, we also have IPO plan in future.

Financials

	2020	2021	2022
Revenue	\$100,000	\$200,000	\$2200,000
Closing cash balance	\$800,000	\$800,000	\$2000,000

Management

The chairman Mr. Shen and the General Manager Mr. Dong are the main executives, who are much experienced in medical device sales in China market.

The CTO Dr. Yuan, having more than ten years research experience in Biodegradable Mg alloys, are running the R&D team of the company.

Achievements

The GMP workshop has been established. The big animal experiments have been completed. 14 clinical trials have been performed and verified the advantages of our products. We are applying the license for clinical use.

General information

Sector: Medical devices manufacturing

Stage: Rapid growth stage

Year established: 2014

Number of staff: 20

Projected breakeven date, if applicable: 2022

Country of origin



China

Contact

Dr. Guangyin Yuan Em

Email: gyyuan@sjtu.edu.cn